San Diego biotech starts clinical study of self-replicating RNA vaccine for rabies
Replicate Bioscience, a biotech startup designing next-generation mRNA vaccines to trigger stronger and longer-lasting immune responses, has begun its first clinical study, the San Diego company announced Tuesday.
The trial, which comes two years after the company launched with $40 million, is likely the first among clinical efforts put forth by a crop of new mRNA startups that emerged during the pandemic. These companies were founded on the belief that new and improved forms of RNA technologies will be needed to make the technology work for conditions beyond Covid-19.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.